Drug development based on an "innovation supply chain" could stifle innovation if drugmakers push small biotech partners to follow a set route, writes Katrine Bosley, former CEO of Avila Therapeutics. "The more innovative the science, the more likely it is that the real challenge is to cultivate a new vision," she writes. Two-way, iterative partnerships bring together big drugmakers' experience with small biotechs' innovation, Bosley writes.
Innovation supply chain model risks "teaching to the test"
SmartBrief Job Listings for Health Care
|Chief Medical Officer||
|Vice President, Public Policy and Communications||
National Committee for Quality Assurance
|Counsel II – Corporate Legal Affairs||
|Foster City, CA|
|Senior Medical Director||
Martin's Point Health Care
|Legal & Regulatory Analysis Specialist||
Health Care Service Corporation